Data Insights

AFM-24I by Affimed for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

Acimtamig by Affimed for Transformed Mycosis Fungoides: Likelihood of Approval

Acimtamig is under clinical development by Affimed and currently in Phase II for Transformed Mycosis Fungoides. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Acimtamig in Transformed Mycosis Fungoides

Data Insights

AFM-24I by Affimed for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

Acimtamig by Affimed for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval

Acimtamig is under clinical development by Affimed and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Acimtamig in Anaplastic Large Cell Lymphoma (ALCL)

Data Insights

AFM-24I by Affimed for Glioblastoma Multiforme (GBM): Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Glioblastoma Multiforme (GBM)

Data Insights

AFM-24I by Affimed for Gastric Cancer: Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Gastric Cancer

Data Insights

AFM-24I by Affimed for Pancreatic Cancer: Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Pancreatic Cancer

Data Insights

AFM-24I by Affimed for Head And Neck Cancer: Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Head And Neck Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Head And Neck Cancer

Data Insights

AFM-24I by Affimed for Cervical Cancer: Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Cervical Cancer

Data Insights

AFM-24I by Affimed for Ovarian Cancer: Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Ovarian Cancer

Data Insights

Acimtamig by Affimed for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval

Acimtamig is under clinical development by Affimed and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Acimtamig in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy

Data Insights

Acimtamig by Affimed for Cutaneous T-Cell Lymphoma: Likelihood of Approval

Acimtamig is under clinical development by Affimed and currently in Phase II for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Acimtamig in Cutaneous T-Cell Lymphoma

Data Insights

Acimtamig by Affimed for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

Acimtamig is under clinical development by Affimed and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Acimtamig in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

AFM-24I by Affimed for Metastatic Renal Cell Carcinoma: Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Metastatic Renal Cell Carcinoma

Data Insights

AFM-24I by Affimed for Lung Cancer: Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Lung Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Lung Cancer

Data Insights

AFM-24I by Affimed for Colorectal Cancer: Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Colorectal Cancer

Data Insights

AFM-24I by Affimed for Non-Small Cell Lung Cancer: Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Data Insights

AFM-24I by Affimed for Metastatic Renal Cell Carcinoma: Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData,...

Data Insights

AFM-24I by Affimed for Lung Cancer: Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Lung Cancer. According to GlobalData, Phase II...

Data Insights

AFM-24I by Affimed for Colorectal Cancer: Likelihood of Approval

AFM-24I is under clinical development by Affimed and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...